Roche

In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
Xconomy
Roche
Foundation Medicine
M&A
Flag link:
Roche CEO Severin Schwan isn’t about to tamper with a winning R&D strategy now, but he’s still looking for ways to cut costs
Roche CEO Severin Schwan isn’t about to tamper with a winning R&D strategy now, but he’s still looking for ways to cut costs
Endpoints
Roche
Pharma CEOs
Severin Schwan
R&D
Flag link:
AbbVie, Roche post a big win with a blockbuster FDA OK for Venclexta/Rituxan combo for leukemia
AbbVie, Roche post a big win with a blockbuster FDA OK for Venclexta/Rituxan combo for leukemia
Endpoints
AbbVie
Roche
Venclexta
Rituxan
CLL
chronic lymphocytic leukemia
Flag link:
Roche's multiple sclerosis drug Ocrevus lowered patients' vaccine responses: study
Roche's multiple sclerosis drug Ocrevus lowered patients' vaccine responses: study
Fierce Pharma
Roche
MS
multiple sclerosis
Ocrevus
FDA
vaccines
Flag link:
ASCO18: Who were the big winners and losers?
ASCO18: Who were the big winners and losers?
Biopharma Dive
ASCO 2018
Merck
Loxo Oncology
Bluebird Bio
Celgene
Roche
Nektar
Flag link:
Roche scrambles to boost Herceptin supply in China after insurance OK triggers shortage
Roche scrambles to boost Herceptin supply in China after insurance OK triggers shortage
Fierce Pharma
Roche
Herceptin
China
Flag link:
Roche dumps its PhIII PI3K effort on taselisib after researchers track poor survival edge, harsh side effects for breast cancer
Roche dumps its PhIII PI3K effort on taselisib after researchers track poor survival edge, harsh side effects for breast cancer
Endpoints
Roche
taselisib
fulvestrant
metastatic breast cancer
ASCO 2018
Flag link:
ASCO18: Tecentriq scores again in lung cancer, but Keytruda looms in background
ASCO18: Tecentriq scores again in lung cancer, but Keytruda looms in background
Biopharma Dive
Roche
Tecentriq
ASCO 2018
chemotherapy
advanced squamous non-small cell lung cancer
Flag link:
Roche scraps €120M SMA drug after hitting ‘many difficulties’
Roche scraps €120M SMA drug after hitting ‘many difficulties’
Fierce Biotech
Roche
SMA
spinal muscular atrophy
Olesoxime
Flag link:
5 Best-Selling Orphan Drugs in the U.S.
5 Best-Selling Orphan Drugs in the U.S.
Motley Fool
orphan drugs
Celgene
Revlimid
Roche
Rituxan
Teva Pharmaceutical
Copaxone
Opdivo
Bristol-Myers Squibb
Merck
Keytruda
Flag link:
Celltrion resubmits Rituxan candidate in US, Herceptin version to follow
Celltrion resubmits Rituxan candidate in US, Herceptin version to follow
Biopharma Reporter
Celltrion
Rituxan
biosimilars
FDA
Herceptin
Roche
Biogen
CT-P10
Flag link:
Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results
Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results
Xconomy
clinical trials
Roche
Genentech
Genmab
JNJ
cancer
Tecentriq
Darzalex
Flag link:
Roche’s Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers
Roche’s Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers
Endpoints
Roche
Tecentriq
anti-PD-L1
non-squamous non-small cell lung cancer
Merck
Bristol-Myers Squibb
Flag link:
Alzheimer’s Disease: Companies Weigh Revised FDA Draft Guidance
Alzheimer’s Disease: Companies Weigh Revised FDA Draft Guidance
RAPS.org
Alzheimer's disease
FDA
Roche
AstraZeneca
Bioclinica
Eli Lilly
Denali Therapeutics
Flag link:
FDA warns of decreased survival in 2 studies of Keytruda, Tecentriq
FDA warns of decreased survival in 2 studies of Keytruda, Tecentriq
Biopharma Dive
FDA
clinical trials
oncologists
bladder cancer
Merck
Keytruda
Roche
Tecentriq
Flag link:
Roche drug dramatically reduces bleeds in key hemophilia tests
Roche drug dramatically reduces bleeds in key hemophilia tests
Reuters
Roche
Hemlibra
clinical trials
hemophilia A
Flag link:
Roche pens death notice for NewLink IDO/TDO cancer collaboration
Roche pens death notice for NewLink IDO/TDO cancer collaboration
Fierce Biotech
Roche
NewLink Genetics
IDO/TDO inhibitors
drug development
Flag link:
Roche Tecentriq and Cotellic Combination Fails Ph III Trial in Colorectal Cancer
Roche Tecentriq and Cotellic Combination Fails Ph III Trial in Colorectal Cancer
CP Wire
Roche
Exelixis
Tecentriq
Cotellic
colorectal cancer
Flag link:
Roche Tecentriq and Cotellic Combination Fails Ph III Trial in Colorectal Cancer
Roche
Exelixis
Tecentriq
Cotellic
Flag link:
FDA promises Roche a snap decision on Tecentriq triple for frontline lung cancer as it falls even further behind Merck, Bristol-Myers
FDA promises Roche a snap decision on Tecentriq triple for frontline lung cancer as it falls even further behind Merck, Bristol-Myers
Endpoints
Roche
Tecentriq
FDA
Genentech
lung cancer
Flag link:

Pages